We are live on ! Find out more
SVA

Sinovac Biotech, Ltd
SVA

Delisted

SVA was delisted on the 22nd of February, 2019.

Back to rankings

35 hedge funds and large institutions have $127M invested in Sinovac Biotech, Ltd in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 10

8% more capital invested

Capital invested by funds: $118M → $127M (+$9.68M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

5% less funds holding

Funds holding: 37 → 35 (-2)

17% less call options, than puts

Call options by funds: $176K | Put options by funds: $212K

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

Holders
35
Holders Change
-2
Holders Change %
-5.41%
% of All Funds
0.87%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
4
Increased
12
Reduced
10
Closed
6
Calls
$176K
Puts
$212K
Net Calls
-$36K
Net Calls Change
-$85K

Top Buyers

Rank Fund Capital Flow
1
GP
GLG Partners
United Kingdom
+$3.25M
2
Renaissance Technologies
Renaissance Technologies
New York
+$2.43M
3
Deutsche Bank
Deutsche Bank
Germany
+$1.23M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$402K
5
Citadel Advisors
Citadel Advisors
Florida
+$233K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$2.41M
2
Invesco
Invesco
Georgia
-$742K
3
SIM
Spark Investment Management
New York
-$174K
4
PAM
Panagora Asset Management
Massachusetts
-$174K
5
Goldman Sachs
Goldman Sachs
New York
-$79K
Name Holding Trade Value Shares
Change 		Change in
Stake
VF
26
Virtu Financial
New York
$71K +$69.1K +10,119 New
IA
27
IFP Advisors
Florida
$14K – – –
UBS Group
28
UBS Group
Switzerland
$14K +$7.16K +1,048 +105%
Simplex Trading
29
Simplex Trading
Illinois
$12K -$48 -7 -0.4%
Wells Fargo
30
Wells Fargo
California
$9K – – –
Carson Wealth (CWM LLC)
31
Carson Wealth (CWM LLC)
Nebraska
$4K – – –
LTFS
32
Ladenburg Thalmann Financial Services
Florida
$2K – – –
GWM
33
Geneos Wealth Management
Colorado
$1K – – –
Walleye Trading
34
Walleye Trading
New York
$346 +$6.57K +962 +2%
Invesco
35
Invesco
Georgia
– -$742K -109,967 Closed
PAM
36
Panagora Asset Management
Massachusetts
– -$174K -25,805 Closed
Goldman Sachs
37
Goldman Sachs
New York
– -$79K -11,668 Closed
AIM
38
Acrospire Investment Management
Illinois
– -$34K -5,030 Closed
FPF
39
FNY Partners Fund
New York
– -$33K -5,000 Closed
TRCT
40
Tower Research Capital (TRC)
New York
– -$5.59K -819 -92%
Creative Planning
41
Creative Planning
Kansas
– -$3K -500 Closed
1
2

SVA Hedge Fund Activity: Q3 2017 in Review

35 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q3 2017, worth a combined $127M — up 8.2% from $118M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of SVA and 4 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 12 added.

The largest buyer was GLG Partners, adding an estimated $3.25M. The largest seller was Morgan Stanley, cutting an estimated $2.41M.

  • 35 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q3 2017, down from 37 in Q2 2017.
  • Funds reported $127M of Sinovac Biotech, Ltd stock for Q3 2017, up 8.2% quarter-over-quarter.
  • 4 funds opened new Sinovac Biotech, Ltd positions in Q3 2017 and 6 closed out, a net change of -2 holders.
  • The largest Sinovac Biotech, Ltd buyer in Q3 2017 was GLG Partners, an estimated $3.25M added.
  • The largest Sinovac Biotech, Ltd seller in Q3 2017 was Morgan Stanley, an estimated $2.41M sold.

Based on aggregated 13F filings for Q3 2017.